Amedica received FDA 510(k) clearance for expanded sizes of the Valeo® II Lateral Lumbar silicon nitride interbody fusion device. Product launch will occur within the month, including second-generation instrumentation.
Valeo II LL is indicated for intervertebral body fusion in skeletally mature patients and is designed for use with autograft. The first iteration of the system launched in 3Q15, and was preceded by anterior lumbar and transforaminal lumbar versions.
Sources: Amedica Corporation, ORTHOWORLD Inc.
Amedica received FDA 510(k) clearance for expanded sizes of the Valeo® II Lateral Lumbar silicon nitride interbody fusion device. Product launch will occur within the month, including second-generation instrumentation.
Valeo II LL is indicated for...
Amedica received FDA 510(k) clearance for expanded sizes of the Valeo® II Lateral Lumbar silicon nitride interbody fusion device. Product launch will occur within the month, including second-generation instrumentation.
Valeo II LL is indicated for intervertebral body fusion in skeletally mature patients and is designed for use with autograft. The first iteration of the system launched in 3Q15, and was preceded by anterior lumbar and transforaminal lumbar versions.
Sources: Amedica Corporation, ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
